View larger
Human anti-hepatitis A virus IgG antibody,anti-HAV ELISA Kit
NB-E10553
Human anti-hepatitis A virus IgG antibody,anti-HAV ELISA Kit For research use only. Not for use in diagnostic procedures.For general protocol and instruction, please click the following links:Quantitative Elisa Kit InstructionSandwich ELISA kit
Data sheet
| Validity | 12 to 18 months from manufacture date |
| Application | The HAV IgG ELISA test is an enzyme-linked immunosorbent assay (ELISA) which is used for the qualitative determination of IgG-class antibodies to hepatitis A virus (HAV-IgG) in serum/plasma. The purpose of the HAV IgG ELISA Test is for laboratory testing, where diagnosing and monitoring of patients suspected of hepatitis A virus takes place |
| Background | Infections usually onset in early childhood, HAV can adversely affect the liver, but acute complications or chronic illness do not necessarily occur because Hepatitis A is a self-limited disease. Causes of the infection are connected to unsanitary conditions and poor hygiene within densely populated areas. Thus, the fecal-oral route of the disease is easily transmitted in this type of setting. One single infected person could cause an entire outbreak. Hepatitis A is a non-enveloped positive strand RNA virus with a linear single strand genome, encoded for only one known serotype. Within HAV are four major, structural polypeptides, concentrated exclusively in the cytoplasm of human hepatocites. An HAV infection causes a strong immunological response, and within a few days after the onset of symptoms, elevated levels of IgM, and subsequently IgG, are identified. Past infection and immunity to HAV are indicated by the presence of IgG. Thus, the phase, classification, and source of the infection can be confirmed when the serological identification of HAV IgG is known. |
| Assay principle | The principle method of the HAV IgG ELISA is a solid phase assay that features a one-step incubation competitive principle. When HAV IgG antibodies are present, they compete with monoclonal HAV IgG antibodies designated with horseradish peroxidase (HRP-Conjugate) for a fixed amount of purified HAV antigens that were pre-coated in the wells. If HAV IgG is not present, HAV IgG (HRP labeled) will be bound together with antigens inside the wells. In the course of washing, the unbound HRP-Conjugate is removed. After chromogen solutions A and B are added into the wells and during incubation, a bluecolored product appears when the colorless chromogens are hydrolyzed by the bound HRP-Conjugate. After the reaction is stopped with sulfuric acid, the blue color turns yellow. A presence of antibodies to HAV in the sample are indicated by a low or no color at all. |
| Assay Type | Indirect qualititative ELISA |
| Kit Type | Colorimetric ELISA |
| Assay Time | 75 min |
| Sample Type | Serum |
| Assay Range | Qualitative Positive; Negative control & Cut off |
| Sensitivity | 100% |
| Specificity | 100% |
| Sample Volume | 50 uL Serum |
| Storage | 2-8°C |
More info
Human anti-hepatitis A virus IgG antibody,anti-HAV ELISA Kit
| Clinical Sensitivity: | |||||
| CHILDREN SENSITIVITY | |||||
| Tested | - | + | Confirmed | ||
| Inapparent infection | 358 | 8 | 350 | 350 | 100% |
| Anicteric / icteric | 234 | 186 | 50 | 50 | 100% |
| Complete recovery | 500 | 0 | 500 | 500 | 100% |
| TOTAL | 1092 | 192 | 900 | 900 | 100% |
| ADULTS SENSITIVITY | |||||
| Tested | - | + | Confirmed | ||
| Inapparent infection | 300 | 233 | 67 | 67 | 100% |
| Anicteric / icteric | 540 | 61 | 480 | 480 | 100% |
| Complete recovery | 570 | 0 | 570 | 570 | 100% |
| TOTAL | 1410 | 293 | 1117 | 1117 | 100% |